Axsome Therapeutics Inc. (NASDAQ: AXSM) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 3 articles on AXSM since May 4, 2026, most recently "AXSM Q2 2026: Revenue Jumps 46% but SG&A Surge to $208M Widens Net Loss" on Tuesday, August 11, 2026. Coverage to date spans Earnings Report, tracking AXSM's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Price
$210.63
Today
+1.35%
Mkt Cap
$11.0B
52W High
$260.19
52W Low
$112.90
Data via Finnhub · refreshes hourly · not financial advice
Auvelity drove 51% sales growth, but a 59.7% spike in SG&A expenses pushed AXSM's Q2 EPS to -$0.99, missing the -$0.86 consensus.
AXSM surged 8.31% to $223.70, clearing its prior 52-week high, after Q1 2026 revenue of $191.2M topped estimates. Launch costs remain a near-term drag on profitability.
AXSM posted Q1 2026 revenue of $191.2M, up sharply year-over-year, but reported a net loss of $64.5M as commercial launch spending weighed on margins.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.